From:
`To:
`Cc:
`Subject:
`Date:
`Attachments:
`
`Alyson Berliner
`Dave Brown
`"Deneva Zamora"
`FW: ARVO late breakers
`Monday, March 1, 2010 2:09:00 PM
`ARVO DRAFT VEGF Trap-EYe DME abstract 022610.doc
`
`Dave,
`
`Any thoughts about the abstract?
`
`Thanks,
`Alyson
`
`
`
`From: Alyson Berliner
`Sent: Friday, February 26, 2010 3:54 PM
`To: Dave Brown
`Subject: RE: ARVO late breakers
`
`OK. If you think it will work…. Thanks!! I guess if it doesn’t, could Matt be a back up?
`
` I
`
` am attaching a draft of the abstract. Let me know what you think. We can finalize on Monday.
`
`
`Thanks and have a great weekend!
`Alyson
`
`
`
`From: Dave Brown [mailto:dmbmd@houstonretina.com]
`Sent: Friday, February 26, 2010 9:59 AM
`To: Alyson Berliner
`Subject: Re: ARVO late breakers
`
`Its probably fine but what is your back-up plan?
`
`I logged in and it allows my ARVO number to be used. The check boxes that “I affirm” don’t ask the
`previous submission question.
`
`Its up to you.-- I’d love to present it but its remotely possible they will check after the fact.
`
`DMB
`
`On 2/26/10 7:52 AM, "Alyson Berliner" <Alyson.Berliner@regeneron.com> wrote:
`
`Hi Dave! Thanks… I was looking on the ARVO website for the submission guidelines and found this
`statement: Late-Breaking Abstracts may be submitted only by a First Author who did not previously
`submit an abstract for the 2010 ARVO Annual Meeting. (http://www.arvo.org/eweb/dynamicpage.aspx?
`site=am2010&WebCode=absubmissionguide)
`
`Do you think it’s still OK if you submit? Is there any way we can find out for sure?
`
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2077 Page 1
`
`

`

`Thanks!
`Alyson
`
`
`From: Dave Brown [mailto:dmbmd@houstonretina.com]
`Sent: Thursday, February 25, 2010 7:45 PM
`To: Alyson Berliner
`Subject: Re: ARVO late breakers
`Importance: High
`
`Sure-- I’m you’re boy. Because I was nuked-- I’m still fair game.
`
`DMB
`
`On 2/25/10 4:14 PM, "Alyson Berliner" <Alyson.Berliner@regeneron.com> wrote:
`Hi Dave,
`
`How are you? Hope all is well…
`
`We are trying to find someone interested in submitting the DA VINCI data as a late breaker to ARVO
`(abstract due next Wednesday). The only problem is, it has to be someone that has not submitted
`anything already. I know you submitted the VIEW 1 abstract, but I am not sure that counts as it wasn’t
`accepted. If you aren’t already presenting something else, would you be interested? Or maybe Matt?
`
`Thanks,
`Alyson
`
`
`
`Alyson J Berliner, MD,PhD
`Director, Clinical Sciences, Ophthalmology
`Regeneron Pharmaceuticals
`(914) 785-3049 (office)
`(914) 815-8875 (mobile)
`(914) 593-1555 (fax)
`Alyson.Berliner@regeneron.com
`
`This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above
`and may contain legally privileged and/or confidential information. If you are not the intended
`recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment
`hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return
`electronic mail and permanently delete this email and any attachment hereto, any copy of this e-
`mail and of any such attachment, and any printout thereof. Finally, please note that only authorized
`representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to enter into
`business dealings with any third party.
` This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above
`and may contain legally privileged and/or confidential information. If you are not the intended
`recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment
`hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return
`electronic mail and permanently delete this email and any attachment hereto, any copy of this e-
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2077 Page 2
`
`

`

`mail and of any such attachment, and any printout thereof. Finally, please note that only authorized
`representatives of Regeneron Pharmaceuticals, Inc. have the power and authority to enter into
`business dealings with any third party.
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2077 Page 3
`
`